Biomarkers play an important role in medical research, and their use is being advocated in the detection, diagnosis, staging, treatment and management of a variety of diseases, including cancer. Using novel genomic and proteomic technologies, new biomarkers are constantly being discovered. Biomarkers are viewed by some as the most critical component in moving forward translational research in cancer. They are central to the critical path, articulated by the FDA, for enhancing drug development. There are several areas where statistical consideration would enhance the utility of biomarkers. First, many researchers have suggested that a single biomarker will be insufficient for prediction and that a panel of biomarkers will be necessary. This leads to the question of how to combine the biomarkers in an """"""""optimal"""""""" manner. Second, many of the candidate biomarkers might be used as surrogate endpoints in randomized trials. Finally, for many biomarkers assumptions of monotonicity are a-priori known, e.g. increasing levels of biomarker are associated with increased disease risk. It would be valuable to have available statistical procedures that make use of this knowledge to improve the utility of the biomarkers. In this grant, we will be developing several new statistical modeling procedures for biomarker data in cancer studies. They are summarized in the following aims:
Specific Aim 1 : Development of semiparametric and nonparametric multivariate isotonic regression modelling procedures for biomarkers. (a) Two-stage estimation procedures for bivariate isotonic regression models and attendant nonparametric and semiparametric profile likelihood ratio inference procedures. (b) Isotonic estimation methods with ordered categorical covariates for censored data.
Specific Aim 2 : Development of statistical methods for the analysis of surrogate endpoints in a single-trial and multiple-trial framework. (a) Counterfactual-based modelling approach to the analysis of surrogate endpoints. (b) Shrinkage estimation approaches to the analysis of surrogate endpoints. (c) Semi-competing risks methodology for the analysis of surrogate endpoints.
Specific Aim 3 : Development of hybrid model averaging methods and attendant projection-based framework for combining biomarkers to optimize predictive accuracy.

Public Health Relevance

Statistical Methods for Cancer Biomarkers. Biomarkers are measurements that can be taken from patient, for example from a simple blood test. Biomarkers do not measure how the patients feel or symptoms they have, never-the-less they may be very useful to give early detection of a disease, or to monitor how the treatment is working, or to assess whether a new treatment if effective.
The aim of this grant is to develop valid methods of analyzing datasets of biomarkers, that get the most information out of the data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA129102-02
Application #
7753158
Study Section
Special Emphasis Panel (ZRG1-HOP-T (08))
Program Officer
Feuer, Eric J
Project Start
2009-01-01
Project End
2011-12-31
Budget Start
2010-01-01
Budget End
2010-12-31
Support Year
2
Fiscal Year
2010
Total Cost
$252,698
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Biostatistics & Other Math Sci
Type
Schools of Public Health
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Shen, Jincheng; Wang, Lu; Taylor, Jeremy M G (2017) Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models. Biometrics 73:635-645
Conlon, Asc; Taylor, Jmg; Elliott, M R (2017) Surrogacy assessment using principal stratification and a Gaussian copula model. Stat Methods Med Res 26:88-107
Conlon, Anna; Taylor, Jeremy; Li, Yun et al. (2017) Links between causal effects and causal association for surrogacy evaluation in a gaussian setting. Stat Med 36:4243-4265
Prince, Victoria; Bellile, Emily L; Sun, Yilun et al. (2016) Individualized risk prediction of outcomes for oral cavity cancer patients. Oral Oncol 63:66-73
Ghosh, Debashis (2016) A modified risk set approach to biomarker evaluation studies. Stat Biosci 8:395-406
Boonstra, Philip S; Taylor, Jeremy Mg; Mukherjee, Bhramar (2016) Increasing efficiency for estimating treatment-biomarker interactions with historical data. Stat Methods Med Res 25:2959-2971
Rizopoulos, Dimitris; Taylor, Jeremy M G; Van Rosmalen, Joost et al. (2016) Personalized screening intervals for biomarkers using joint models for longitudinal and survival data. Biostatistics 17:149-64
Foster, Jared C; Nan, Bin; Shen, Lei et al. (2016) Permutation Testing for Treatment-Covariate Interactions and Subgroup Identification. Stat Biosci 8:77-98
Taylor, Jeremy M G; Conlon, Anna S C; Elliott, Michael R (2015) Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models. Clin Trials 12:317-22
Elliott, Michael R; Conlon, Anna S C; Li, Yun et al. (2015) Surrogacy marker paradox measures in meta-analytic settings. Biostatistics 16:400-12

Showing the most recent 10 out of 49 publications